Serodus ASA Stock

Stocks

17-01-02	Serodus : Primary endpoint reached by SER150 Phase 2a study in Diabetic Nephropathy.	PU
16-12-08	Serodus : Q&A delisting from Oslo Axess	PU
16-11-23	Serodus : Extraordinary general meeting held	PU
16-11-23	Serodus : Viggo Harboe Holding 2006 ApS announces results of voluntary offer	PU
16-11-02	Serodus : Viggo Harboe Holding 2006 Aps Launces voluntary offer for outstanding shares in Serodus ASA – Acceptance period starting 31 October 2016	PU

1 day

-5.56%

Manager	Title	Age	Since
Arnstein Gunnestad Endresen CEO	Chief Executive Officer	73	2022-12-31
Henrik Mordhorst DFI	Director of Finance/CFO	-	2019-09-30
Daniel Capion PRN	Corporate Officer/Principal	-	2020-12-31

Director	Title	Age	Since
Søren Elmann Ingerslev CHM	Chairman	-	2016-12-31
Terri Sebree BRD	Director/Board Member	68	2014-03-31
Viggo Gunnersen Harboe BRD	Director/Board Member	80	2021-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERODUS ASA	-5.56%	+7.94%	-	-	0
WUXI APPTEC CO., LTD.	-1.59%	-3.35%	+52.37%	+91.62%	69.54B
ARGENX SE	-2.12%	+1.39%	+44.64%	+88.51%	64.97B
WUXI BIOLOGICS (CAYMAN) INC.	-3.57%	-4.24%	+47.11%	+5.60%	26.51B
INSMED INCORPORATED	+1.72%	-4.21%	-18.27%	+442.53%	25.89B
BIONTECH SE	-0.42%	-9.95%	+0.96%	-15.99%	25.64B
PHARMAESSENTIA CORPORATION	-0.96%	+10.36%	+283.06%	+429.04%	20.22B
GENMAB A/S	-1.58%	+0.33%	+29.17%	-19.73%	19.98B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.36%	-7.58%	+9.47%	+535.81%	15.69B
EXELIXIS, INC.	-0.61%	-0.71%	+45.68%	+141.92%	13.49B
Average	-1.79%	-1.93%	+54.91%	+188.81%	31.33B
Weighted average by Cap.	-1.48%	-1.50%	+51.13%	+148.68%

Employees

Sector